Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenzhen Oralead Pharma Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, YOUNG, MICAH PAUL. As the only examiner involved, YOUNG, MICAH PAUL is the busiest examiner. The prosecution is situated in 1 distinct art unit. This indicates a very specific and limited current engagement with the patent office for the company.
With 1 pending office action, the company's current prosecution is entirely focused on a single application. YOUNG, MICAH PAUL is the sole individual responsible for reviewing this case within 1 distinct art unit. This concentration means the company's current patent goals in the Biotechnology & Pharmaceuticals technology area are tied to the outcome of this 1 pending office action. The use of 1 distinct examiner and 1 distinct art unit reflects a highly targeted approach to its current intellectual property filings. This strategy allows the company to concentrate its efforts on a single pharmaceutical innovation, though it lacks the risk mitigation provided by a larger, more diverse portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | YOUNG, MICAH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19194059 | ORAL POLYPEPTIDE COMPOSITION | YOUNG, MICAH PAUL | 1618 | §103 | Non-Final OA | — | Pending | Apr 30, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial